BioSpace News Archive

Belite Bio, Inc announced that it has priced an underwritten public offering of 2,000,000 American Depositary Shares, each representing one of its ordinary shares, and warrants to purchase 2,000,000 ordinary shares represented by ADSs, at a public offering price of $15.00 per ADS and accompanying warrant.

Ascentage Pharma announced that the Center for Drug Evaluation of China National Medical Products Administration has recommended olverembatinib, Ascentage Pharma’s lead novel drug candidate, for a Breakthrough Therapy Designation for the treatment of patients with succinate dehydrogenase -deficient gastrointestinal stromal tumor who had received first-line treatment.

Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers has released the Company’s 1Q2023 unaudited condensed interim consolidated Financial Statements.

Miromatrix Medical Inc. announced it will be presenting at the upcoming 2023 American Transplant Congress held on June 3rd to June 7th, 2023 in San Diego, California.

Kodiak Sciences Inc., a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced that management will present at the following upcoming investor conferences.

Aceragen, Inc., announced that on May 24, 2023, the Company received a notice from The Nasdaq Stock Market LLC stating that because the Company had not yet filed its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, the Company is not in compliance with Nasdaq Listing Rule 5250, which requires timely filing of periodic financial reports with the Securities and Exchange Commission.

Vistagen (Nasdaq: VTGN) today announced that safety and exploratory efficacy data from its Phase 3 open-label study of fasedienol (PH94B) nasal spray for the treatment of adults with social anxiety disorder (SAD) will be presented in a late-breaking poster presentation at the American Society for Clinical Psychopharmacology (ASCP) 2023 Annual Meeting.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company developing novel molecular glue degrader -based medicines, announced the company is scheduled to present at the following investor and industry events in June.

Neogen® Corporation announced that the Company will participate in the 43rd Annual William Blair Growth Stock Conference in Chicago, Illinois, on Tuesday, June 6, 2023.

According to our new research study on “Medical Enzyme Technology Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Enzyme Type and Application